CBFB and acute myeloid leukemia: The consensus document from the ELN MRD Working Party indicates that AML patients with NPM1 mutations, such as patients with RUNX1-RUNX1T1, CBFb-MYH11 or PML-RARA fusion transcripts, should have molecular MRD assessment at informative clinical timepoints.